GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin +/- Sulfonylurea (GETGOAL-L-ASIA)

NCT00866658 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

311

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG: Lixisenatide (AVE0010)
DRUG: Placebo
DEVICE: Pen auto-injector
DRUG: Sulfonylurea
DRUG: Basal Insulin

Sponsor

Sanofi